These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 12142636)
21. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Bergemann N; Frick A; Parzer P; Kopitz J Pharmacopsychiatry; 2004 Mar; 37(2):63-8. PubMed ID: 15048613 [TBL] [Abstract][Full Text] [Related]
22. [Analysis of olanzapine in human plasma with reversed-phase high performance liquid chromatography]. Xiao H; Xie SP; Fan JX; Yao H; Han G Se Pu; 2001 May; 19(3):281-2. PubMed ID: 12541820 [TBL] [Abstract][Full Text] [Related]
23. Integration of olanzapine determinations in a HPLC-diode array detection system for routine psychotropic drug monitoring. Llorca PM; Coudore F; Corpelet C; Buyens A; Hoareau M; Eschalier A Clin Chem; 2001 Sep; 47(9):1719-21. PubMed ID: 11514415 [No Abstract] [Full Text] [Related]
24. Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. Olesen OV; Poulsen B; Linnet K Ther Drug Monit; 2001 Feb; 23(1):51-5. PubMed ID: 11206044 [TBL] [Abstract][Full Text] [Related]
26. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. Penzak SR; Hon YY; Lawhorn WD; Shirley KL; Spratlin V; Jann MW J Clin Psychopharmacol; 2002 Aug; 22(4):366-70. PubMed ID: 12172335 [TBL] [Abstract][Full Text] [Related]
27. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Aravagiri M; Ames D; Wirshing WC; Marder SR Ther Drug Monit; 1997 Jun; 19(3):307-13. PubMed ID: 9200772 [TBL] [Abstract][Full Text] [Related]
29. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Fellows L; Ahmad F; Castle DJ; Dusci LJ; Bulsara MK; Ilett KF Ther Drug Monit; 2003 Dec; 25(6):682-9. PubMed ID: 14639054 [TBL] [Abstract][Full Text] [Related]
30. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. Boulton DW; Markowitz JS; DeVane CL J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(2):319-23. PubMed ID: 11499485 [TBL] [Abstract][Full Text] [Related]
31. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. Chiu JA; Franklin RB J Pharm Biomed Anal; 1996 Mar; 14(5):609-15. PubMed ID: 8738191 [TBL] [Abstract][Full Text] [Related]
32. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Castberg I; Spigset O Pharmacopsychiatry; 2007 May; 40(3):107-10. PubMed ID: 17541885 [TBL] [Abstract][Full Text] [Related]
33. Olanzapine concentrations in clinical serum and postmortem blood specimens--when does therapeutic become toxic? Robertson MD; McMullin MM J Forensic Sci; 2000 Mar; 45(2):418-21. PubMed ID: 10782964 [TBL] [Abstract][Full Text] [Related]
34. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Kelly DL; Conley RR; Tamminga CA Schizophr Res; 1999 Nov; 40(2):101-4. PubMed ID: 10593449 [TBL] [Abstract][Full Text] [Related]
35. Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. Lu ML; Lin CH; Chen YC; Yang HC; Wu TH PLoS One; 2013; 8(5):e65719. PubMed ID: 23741510 [TBL] [Abstract][Full Text] [Related]
36. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Alfaro CL; Wudarsky M; Nicolson R; Gochman P; Sporn A; Lenane M; Rapoport JL J Child Adolesc Psychopharmacol; 2002; 12(2):83-91. PubMed ID: 12188977 [TBL] [Abstract][Full Text] [Related]
37. Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Bogusz MJ; Krüger KD; Maier RD; Erkwoh R; Tuchtenhagen F J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(2):257-69. PubMed ID: 10517347 [TBL] [Abstract][Full Text] [Related]
38. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. Dusci LJ; Peter Hackett L; Fellows LM; Ilett KF J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jun; 773(2):191-7. PubMed ID: 12031846 [TBL] [Abstract][Full Text] [Related]
39. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054 [TBL] [Abstract][Full Text] [Related]
40. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. Weigmann H; Härtter S; Maehrlein S; Kiefer W; Krämer G; Dannhardt G; Hiemke C J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(1):63-71. PubMed ID: 11499630 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]